Britain became the first country to approve the listing of Monapilavi. Monapira is the first antiviral oral drug to treat COVID-19.
(Monapiravir (in English: Molnupiravir, development codes MK-4482 and Eid-2801) is an antiviral drug jointly developed by Merck Pharmaceutical Company and Ridgeback Therapeutic Company, which can be taken orally. Originally used to treat influenza, it was recently used against COVID-19. It is a prodrug for the synthesis of nucleoside derivative N4- hydroxycytidine, which plays an antiviral role by introducing errors in the process of viral RNA replication. )
Tests of this drug produced by Merck, a pharmaceutical company, and Ridgeback Biotherapeutics, a biotechnology company, show that patients with coronavirus pneumonia-19 risk factors, if they take this drug within five days after symptoms appear, the possibility of hospitalization or death will be reduced by 50%.
Monapiravir was developed by Merck, a German pharmaceutical company, in cooperation with Ridgeback Bio, an American company. Drug tests show that for COVID-19 patients with risk factors, if monapiravir is taken within 5 days before symptoms appear, the severity or mortality will be reduced by 50%.